Claim 1: isolated an Antibody or Antigen binding fragment, It characterized in that: (a) binds to a human complement Component C5； (b) inhibits The decomposition of C5 Fragments C5A and C5B； and (c) includes: (i) a heavy chain that includes the sequence CDR1 Amino Acid id represented in sec.No. 23, (ii) a heavy chain CDR2 comprising the Amino Acid Sequence represented in the ID of sec. No. 19, (iii) a heavy chain CDr3 comprising the Amino Acid Sequence represented in the ID of sec. No. 3, (iv) a CDR1 light chain comprising the Amino Acid Sequence represented in the ID of sec.No. 4, (V) a light chain CDR2 comprising the Amino Acid Sequence represented in the ID of sec. No. 5, and (VI) a light chain CDr3 comprising the Amino Acid Sequence represented in the ID of sec. No. 6.Claim 11 wherein a Nucleic Acid encoding polypeptide of heavy chain of Antibody or Antigen binding Fragment of this Agreement with the claim 6.Claim 18: a Pharmaceutical composition which comprises a pharmaceutically acceptable vehicle and the Antibody or Antigen binding Fragment of this according to any one of claims 1 to 10.Claim 21: An article of manufacture comprising: a container that includes a Label； and a composition characterized by comprising: (i) an isolated Antibody or Antigen binding Fragment of this according to any one of claims 1 to 10, where the Label indicates that the composition is administered to a Human who have, or are suspected to have,Or is at risk of developing, a condition associated with the complement.Claim 22: a method for the treatment of a patient with a condition associated with complement, characterized in that it comprises the Administration to the subject of Antibody or Antigen binding Fragment of this according to any one of claims 1 to 10 co N an effective amount to treat the condition associated with the Supplement.Reivindicación 1: Un anticuerpo aislado, o fragmento de unión al antígeno de este caracterizado porque: (a) se une a un C5 humano de componente de
